Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01969669 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-199
A Phase 1 study of Non-Hodgkin's Lymphoma, sponsored by AbbVie.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 3
- Study locations
NCT01969669 is a Phase 1 study of Non-Hodgkin's Lymphoma that has completed, run by AbbVie. The registered enrollment target is 12 participants, below the 222-participant average among 63 other Non-Hodgkin's Lymphoma trials with a reported enrollment target (95% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT01969669, a Phase 1 study of Non-Hodgkin's Lymphoma, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is an open-label multicenter, study to assess the pharmacokinetic interaction of ketoconazole with ABT-199 in up to 12 subjects with relapsed or refractory non-Hodgkin's lymphoma.
Conditions Studied
Interventions
- DRUG Ketoconazole
- DRUG ABT-199
Study Locations (3)
Arizona
- Site Reference ID/Investigator# 97498 - Tucson
New Hampshire
- Site Reference ID/Investigator# 92593 - Lebanon
New Jersey
- Site Reference ID/Investigator# 101415 - Hackensack
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2013-12 |
| Est. Completion | 2014-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01969669
The ClinicalTrials.gov registry entry for NCT01969669 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 222-participant average among 63 other Non-Hodgkin's Lymphoma trials with a reported enrollment target (95% lower). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Hodgkin's Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Ketoconazole is the first listed.
NCT01969669 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Arizona, New Hampshire, New Jersey.
Frequently Asked Questions
What is clinical trial NCT01969669 about?
NCT01969669 is a clinical study titled "A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-199". This is an open-label multicenter, study to assess the pharmacokinetic interaction of ketoconazole with ABT-199 in up to 12 subjects with relapsed or refractory non-Hodgkin's lymphoma.
What is the current status of trial NCT01969669?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2013-12. Estimated completion is 2014-09.
What conditions does trial NCT01969669 study?
This clinical trial studies the following conditions: Non-Hodgkin's Lymphoma.
What interventions are being tested in trial NCT01969669?
The interventions under investigation include: Ketoconazole (DRUG), ABT-199 (DRUG).
Who is sponsoring clinical trial NCT01969669?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01969669 being conducted?
This trial has 3 study locations across Arizona, New Hampshire, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Hodgkin's Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
RECRUITING · Phase 1
-
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
RECRUITING · Phase 1
-
A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma
RECRUITING · Phase 1
-
Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma
RECRUITING · Phase 1
-
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
RECRUITING · Phase 1
-
Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO)
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.